Saar Gill, MD: Combining CAR T-Cell Therapy With Ibrutinib in CLL Patients

Adding ibrutinib to treatment with CAR T-cell therapy was feasible, led to deeper remissions, and reduced the severity of cytokine release syndrome in patients with chronic lymphocytic leukemia.

• Catégorie